Lusutrombopag is a prescription medicine indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. It is available as tablets for oral use. MedsAcross supplies Lusutrombopag for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. MULPLETA is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Source: US FDA prescribing information
Lusutrombopag is an orally bioavailable, small molecule TPO receptor agonist that interacts with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation.
Source: US FDA prescribing information
Begin MULPLETA dosing 8-14 days prior to a scheduled procedure. Patients should undergo their procedure 2-8 days after the last dose. Recommended Dosage: 3 mg orally once daily with or without food for 7 days.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Thrombotic/Thromboembolic Complications: MULPLETA is a thrombopoietin (TPO) receptor agonist, and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Monitor platelet counts and for thromboembolic events and institute treatment promptly.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in detail in other sections of the labeling: Thrombotic/Thromboembolic Complications The most common adverse reaction (≥3%): headache.
Source: US FDA prescribing information
Store MULPLETA in the original package at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Lusutrombopag, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Mulpleta 3 mg tabletOral | Vancocin Italia | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Lusutrombopag in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Lusutrombopag and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Lusutrombopag, including Mulpleta.
Yes. The US FDA first approved Lusutrombopag on 31 July 2018, according to Drugs@FDA.
No listed presentation of Lusutrombopag is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Lusutrombopag is classified under ATC code B02BX07 (Lusutrombopag).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.